Showing results (321-330 of 683) with videos related to

Sort By:
Pageof 69
Gastroenterology|June 11, 2002
Clinical and pathophysiological characteristics of acute-onset functional dyspepsiaJan Tack, Ingrid Demedts, Geert Dehondt, et al.
Alimentary Pharmacology & Therapeutics|July 27, 2021
Systematic review: duodenogastroesophageal (biliary) reflux prevalence, symptoms, oesophageal lesions and treatmentChamara Basnayake, Annelies Geeraerts, Ans Pauwels, et al.
Hearing Research|August 2, 2008
Neurite outgrowth on cultured spiral ganglion neurons induced by erythropoietinNurdanat Berkingali, Athanasia Warnecke, Priya Gomes, et al.
Neurogastroenterology and Motility|January 25, 2020
Prevalence and impact of self-reported painful and non-painful constipation in the general populationJasper Pannemans, Karen Van den Houte, Benjamin Fischler, et al.
Dysphagia|February 19, 2022
Accuracy of High-Resolution Pharyngeal Manometry Metrics for Predicting Aspiration and Residue in Oropharyngeal Dysphagia Patients with Poor Pharyngeal ContractilityHowell Henrian G Bayona, Nicole Pizzorni, Jan Tack, et al.
Proceedings of the National Academy of Sciences of the United States of America|December 22, 2006
Maternal serotonin is crucial for murine embryonic developmentFrancine Côté, Cécile Fligny, Elisa Bayard, et al.
American Journal of Physiology. Gastrointestinal and Liver Physiology|July 18, 2002
Interstitial cells of Cajal and electrical activity in ganglionic and aganglionic colons of miceSean M Ward, Michael D Gershon, Kathleen Keef, et al.
The American Journal of Gastroenterology|March 31, 2011
Characteristics of acute pain attacks in patients with irritable bowel syndrome meeting Rome III criteriaPer M Hellström, Yuri A Saito, Peter Bytzer, et al.
Scientific Reports|March 31, 2018
Activation of Eosinophils and Mast Cells in Functional Dyspepsia: an Ultrastructural EvaluationHanne Vanheel, Maria Vicario, Werend Boesmans, et al.
Neurogastroenterology and Motility|September 30, 2022
Randomized clinical trial: A double-blind, proof-of-concept, phase 2 study evaluating the efficacy and safety of vonoprazan 20 or 40 mg versus esomeprazole 40 mg in patients with symptomatic gastro-esophageal reflux disease and partial response to a healing dose of a proton-pump inhibitorJan Tack, Borislav Vladimirov, Ivo Horny, et al.
Pageof 69